SCHEMBL352323

SCHEMBL352323

NC(C(=O)O)c1ccc(Br)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 5/20 0.52
KMT2A Q03164 5/20 0.52
TDP1 Q9NUW8 4/20 0.52
MEN1 O00255 4/20 0.52
CYP2C9 P11712 3/20 0.52
CYP2C19 P33261 2/20 0.52
CYP2D6 P10635 1/20 0.52
GRM8 O00222 1/20 0.52
GRM6 O15303 1/20 0.52
SLC6A2 P23975 1/20 0.52
SLC6A4 P31645 1/20 0.52
DRD3 P35462 1/20 0.52
GRM4 Q14833 1/20 0.52
KDM4E B2RXH2 4/20 0.48
ALDH1A1 P00352 4/20 0.48
HPGD P15428 4/20 0.48
GRM1 Q13255 3/20 0.48
GRM2 Q14416 2/20 0.48
LDHA P00338 1/20 0.45
CYP1A2 P05177 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL352322 1.00 HSD17B10 (0.52) HSD17B10KMT2ATDP1MEN1CYP2C9
SCHEMBL28901123 1.00 HSD17B10 (0.52) HSD17B10KMT2ATDP1MEN1CYP2C9
Hydrochloric Acid SCHEMBL28294751 0.98 HSD17B10 (0.50) HSD17B10KMT2ATDP1MEN1CYP2C9
SCHEMBL30057643 0.94 HSD17B10 (0.47) HSD17B10KMT2ATDP1MEN1CYP2C9
SCHEMBL13527786 0.88 HSD17B10 (0.61) HSD17B10KMT2ATDP1MEN1CYP2C9
SCHEMBL3306654 0.82 MEN1 (0.49) KMT2AMEN1CYP2C19CYP1A2ALOX5
Oxfenicine SCHEMBL122315 0.79 HSD17B10 (0.55) HSD17B10KMT2ATDP1MEN1CYP2C9
Oxfenicine SCHEMBL652186 0.79 HSD17B10 (0.55) HSD17B10KMT2ATDP1MEN1CYP2C9
SCHEMBL2262988 0.79 HSD17B10 (0.53) HSD17B10KMT2ATDP1MEN1CYP2C9
SCHEMBL5329159 0.79 HSD17B10 (0.53) HSD17B10KMT2ATDP1MEN1CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-120005341-A Acrylic plate with sound insulation function and preparation process thereof 浙江伸美压克力股份有限公司 2025-05-16 CN claimed
CN-113161452-B Perovskite thin film, perovskite LED device and preparation method thereof 湖北大学 2023-03-24 CN claimed
CN-113161452-A Perovskite thin film, perovskite LED device and preparation method thereof 湖北大学 2021-07-23 CN claimed
US-12503452-B2 Antimicrobial compounds and methods CURZA GLOBAL, LLC (US) 2025-12-23 US disclosed
EP-4225304-B1 SYNTHESIS OF EGFR MODULATORS UNIV MICHIGAN REGENTS (US) 2025-12-17 EP disclosed
CN-120005341-A Acrylic plate with sound insulation function and preparation process thereof 浙江伸美压克力股份有限公司 2025-05-16 CN disclosed
US-20240018144-A1 Synthesis of EGFR Modulators THE REGENTS OF THE UNIVERSITY OF MICHIGAN 2024-01-18 US disclosed
US-20240018144-A1 Synthesis of EGFR Modulators THE REGENTS OF THE UNIVERSITY OF MICHIGAN 2024-01-18 US disclosed
US-20240018144-A1 Synthesis of EGFR Modulators THE REGENTS OF THE UNIVERSITY OF MICHIGAN 2024-01-18 US disclosed
EP-3880659-B1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY NOVARTIS AG (CH) 2024-01-03 EP disclosed
CN-116997551-A Synthesis of EGFR modulators 密歇根大学董事会 2023-11-03 CN disclosed
CN-101248046-A Amide derivatives as kinase inhibitors DEVGEN NV (BE) 2008-08-20 CN disclosed
CN-101238127-A Pyrimidine or triazine fused bicyclic metalloprotease inhibitors ALANTOS PHARMACEUTICALS INC (US) 2008-08-06 CN disclosed
US-20080161300-A1 Heterobicyclic metalloprotease inhibitors ALANTOS PHARMACEUTICALS HOLDING, INC. (US) 2008-07-03 US disclosed
EP-1907362-A1 AMIDE DERIVATIVES AS KINASE INHIBITORS Devgen NV (BE) 2008-04-09 EP disclosed
WO-2007096259-A1 HYDANTOIN BASED KINASE INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2007-08-30 WO disclosed
US-20070197617-A1 Substituted hydantoins CHEN SHAOQING 2007-08-23 US disclosed
US-20070155738-A1 Heterobicyclic metalloprotease inhibitors ALANTOS PHARMACEUTICALS, INC. 2007-07-05 US disclosed
WO-2007006547-A1 AMIDE DERIVATIVES AS KINASE INHIBITORS DEVGEN N.V. (BE) 2007-01-18 WO disclosed
US-20060293345-A1 Heterobicyclic metalloprotease inhibitors ALANTOS PHARMACEUTICALS HOLDING, INC. 2006-12-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070197617-A1 Substituted hydantoins HNMT, HRH3, BRAF HSD17B10 1072/4885KMT2A 179/4885TDP1 554/4885
US-20060293345-A1 Heterobicyclic metalloprotease inhibitors MMP13, MMP3, MMP10 HSD17B10 458/4885KMT2A 3364/4885TDP1 2102/4885
US-20080161300-A1 Heterobicyclic metalloprotease inhibitors MMP13, TIMP3, MMP3 HSD17B10 501/4885KMT2A 3548/4885TDP1 2304/4885
US-20070155738-A1 Heterobicyclic metalloprotease inhibitors MMP13, TIMP3, MMP3 HSD17B10 501/4885KMT2A 3548/4885TDP1 2304/4885
US-20240018144-A1 Synthesis of EGFR Modulators EGFR, ERBB2, ERBB4 HSD17B10 3585/4885KMT2A 3424/4885TDP1 4743/4885
US-12503452-B2 Antimicrobial compounds and methods MPO, NISCH, RPN2 HSD17B10 3006/4885KMT2A 4067/4885TDP1 4219/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.